OpenAlex
PricingAboutJobs
Log inGet started
Work

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

HTML PDF

Year: 2014
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
DOI: 10.1093/annonc/mdu524
Authors: C. Jackisch, S.-B. Kim, V. Semiglazov, B. Melichar, X. Pivot, C. Hillenbach, D. Stroyakovskiy, B.L. Lum, R. Elliott, H.A. Weber, G. Ismael
Institutions: Sana Klinikum Offenbach, Asan Medical Center, University of Ulsan, Institute of Oncology NN Petrov, Palacký University Olomouc, Centre Hospitalier Universitaire de Besançon, F. Hoffmann-La Roche AG, Moscow City Oncology Hospital №62, Genentech, Hospital Amaral Carvalho
Language: English

Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: trastuzumab, subcutaneous administration, intravenous administration, HER2-positive breast cancer, neoadjuvant therapy, adjuvant therapy, pathological complete response, pharmacokinetics, immunogenicity, adverse events, event-free survival, body weight, drug exposure, locally advanced breast cancer, inflammatory breast cancer, non-inferiority, infection, weight-based dosing
SDG: Good health and well-being

Open Access status: bronze

Funder: Javna Agencija za Raziskovalno Dejavnost RS
OpenAlex ID: W2115527794
FWCI: 5.622
Cites: 15
Cited by: 118
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security